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ABSTRACT 
Hypertension is the most common regulating risk factor for cardiovascular disease (CVD) and death; the increased risk associated with blood 
pressure (BP) elevation can be greatly reduced by treatment with antihypertensive drugs that lower both BP and related tar get organ damage. 
New Ca2+ channel antagonists have been recently developed, especially in the DHP compounds that have considerable higher vascular 
selectivity, slower onset and longer duration of hypotensive action. The antihypertensive effect of azelnidipine is primarily based on the 
inhibition of trans-membrane Ca2+ influx through the voltage-dependent channels of vascular smooth muscles. Ca2+ channels are categorized 
into several subtypes, including L-type, T-type, N-type, P/Q-type, and R-type Ca2+ channels depend on their electrophysiological properties.   
Clinical studies have demonstrated that azelnidipine markedly reduced heart rate and proteinuria in hypertensive patients by inhibiting 
sympathetic nerve activity. Azelnidipine has also been confirmed to have cardio-protective, neuroprotective, and anti-atherosclerotic 
properties, and has also been found to prevent insulin resistance.  
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INTRODUCTION 
Over the ancient numerous eras, the term “essential 
hypertension” has become ingrained in our medical 
vocabulary. We not only use it in our usual medical idiom but 
the term was actually codified in ICD-9. As a medical 
community, we do not categorize any other common 
pathological conditions, such as obesity, NIDDM, or CAD as 
“essential.” Additionally, in order to discriminate the 
common variety of hypertension from a particular etiology 
related hypertension so called secondary hypertension the 
most rational substitute term would have been “primary” 
hypertension. But why and how did the term “essential 
hypertension” come approximately? To find the answer, one 
needs to investigate into the history of the pharmacological 
treatment of hypertension. The history of hypertension goes 
back a extensive way. In ancient Chinese and Indian 
Ayurvedic medicine, the quality of an individual’s pulse, as 
felt by moderate palpation by the trained physician, was a 
window into the condition of the cardiovascular system. 
What was called “hard pulse” possibly would qualify for the 
modern term of hypertension. The history of hypertension, is 
incomplete without Akbar Mahomed’s contribution in 
developing the modern concept of hypertension. In the late 
nineteenth century, Frederick Akbar Mahomed (1849–1884), 
an Irish-Indian physician working at Guy’s hospital in 
London, first described conditions that later originated to be 
known as “essential hypertension,” separating it from the 
similar vascular changes seen in chronic glomerulonephritis 
such as Bright’s disease. Some of the significant 
contributions of Akbar Mahomed were the demonstration 
that high BP could exist in apparently healthy individuals, 
that high BP was more likely in older populations, and that 
the heart, kidneys, and brain could be affected by high 
arterial tension. However, only with the advent of the 
mercury sphygmomanometer in the early twentieth century 
and defining of the systolic and diastolic BP by appearance/ 
disappearance of Korotkoff sounds as heard via the 
stethoscope, the modern quantitative concept of 
hypertension – broken into systolic and diastolic categories – 
came into existence. By the middle of the twentieth century, 
checking BP by sphygmomanometer became part of the 
routine physical examination in hospitals and clinics. 
Hypertension, however, was not always considered a disease 
as we know it now. President Franklin D. Roosevelt was 
given a clean bill of health by his physician even when his BP 
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was recorded as ~220/120. A few years later while at Yalta, 
Winston Churchill’s personal physician noted in his diary 
that President Roosevelt “appeared to be had signs of 
‘hardening of the arteries disease’ and had a few months to 
live.” Subsequent events demonstrated the truth of his 
diagnosis. President Roosevelt ultimately had a fatal 
hemorrhagic stroke 2 months later, and his death brought 
hypertension’s potential as a deadly difficulty to the lime 
light. Three years after Roosevelt’s death, the pivotal 
National Heart Act was signed into law by President Truman. 
The Act created the track for the study of heart diseases and 
resulted in several studies including the Framingham Heart 
Study. The Framingham studies consistently showed that 
hypertension, such as hyperlipidemia, was associated with 
many cardiovascular morbidities such as stroke, heart 
failure, and heart attacks leading to premature deaths and 
the risk was clearly higher with higher blood pressure 
(systolic and diastolic).1  
Hypertension is the most common regulating risk factor for 
cardiovascular disease (CVD) and death; the increased risk 
associated with blood pressure (BP) elevation can be greatly 
reduced by treatment with antihypertensive drugs that 
lower both BP and related target organ damage. A total of 69 
drugs in 15 different classes are available and many of them 
are also available in single pill combinations, have been 
approved for the treatment of hypertension in the United 
States. Irrespective of this superfluity of retreatment options, 
an estimated 10% to 15% of the general hypertensive 
population has resistant hypertension, defined as 
uncontrolled BP on ≥3 antihypertensive drugs of different 
classes, including a non-potassium sparing diuretic, at 
optimal doses, or requiring ≥4 drugs to achieve control. In 
addition, ≈0.5% of hypertensive patients has refractory 
hypertension, defined as uncontrolled BP on ≥5 drugs. 
Numerous additional hypertensive patients are uncontrolled 
because of nonadherence or intolerance to available 
antihypertensive agents. Recent drug monitoring studies 
have revealed non-adherence to BP lowering therapy in 25% 
to 65% of patients with apparent treatment resistant 
hypertension (TRH). In 24% to 34.5% of these individuals, 
who were prescribed 3–5+ antihypertensive medications, no 
antihypertensive medication was detected in blood or urine 
samples. The unmet need of controlling BP in these high-risk 
patients may be addressed, in part, by the development of 
new drugs and devices and procedures that are designed to 
treat hypertension and comorbidities, such as heart failure 
(HF), chronic kidney disease, and diabetes mellitus.2,3  
ETIOLOGY 
Etiological factors correlated with hypertension in adults 
have also been associated with blood pressure elevations in 
youth. Intrauterine malnutrition, family history of 
hypertension ,obesity, particularly excess abdominal fat, 
insulin resistance, high dietary sodium intakes, low dietary 
intakes of calcium, potassium and magnesium, physical 
inactivity, high alcohol intakes, tobacco use, drug use (e.g., 
cocaine, ecstasy, anabolic steroids), emotional stress, diet pill 
use, oral contraceptives are the factors associated with 
development of hypertension. An inadequate supply of 
nutrients may program changes in fetal structure and 
metabolism, increasing the risk of hypertension and other 
diseases in later life. Hyperinsulineamia and insulin 
resistance are also associated with the development of 
hypertension which leads to many problems. The prominent 
plasma insulin levels may cause sodium sensitivity. Adequate 
dietary potassium, calcium, and magnesium intakes have 
been associated with lower blood pressure in youth. 
Potassium and calcium intakes are below recommended 
levels, particularly in adolescent females, while median 
intakes of phosphorus and protein, which promote calcium 
loss, are high. Lack of physical activity may increase the risk 
of developing hypertension by 20-50%.4 
CALCIUM CHANNEL BLOCKER: 
Voltage-gated Ca2+ channel: 
In excitable cells such as cardiac myocytes, smooth muscle 
cells and neurons the Voltage-gated Ca2+ channels play 
important roles in excitement-contraction, excitement-
transmission, and/or excitement-transcription couplings. 
High voltage-gated Ca2+ channels are pharmacologically 
classified into five different subclasses (L-, N-, P-, Q-, and R-
type), the characteristics of which are determined by the 
pore-forming α1 subunit. New Ca2+ channel antagonists 
have been recently developed, especially in the DHP 
compounds that have considerable higher vascular 
selectivity, slower onset and longer duration of hypotensive 
action. Those more lipophilic Dihydropyridine Calciun 
channel blockers may reach their receptor, the L-type Ca2+ 
channel, via a membrane pathway with a two-step process: 
first, these drugs bind and accumulate in the membrane lipid 
bilayer, and Then diffuse within the membrane to its 
receptor site.5  
Dual L/N-type Ca2+ channel blockers: 
N-type Ca2+ channels are abundantly found in the nervous 
system particularly in peripheral and central sympathetic 
nerve endings and deeply involved in the fast release of 
norepinephrine and other neurotransmitters. Inhibition of N-
type Ca2+ channels in both peripheral and central nervous 
systems may provide a new strategy for the treatment of 
hypertension and other cardiovascular diseases. To ensure 
efficient coupling of Ca2+ influx to rapid vesicle release, 
N-type Ca2+ channels must be localized with the active zones 
of presynaptic nerve terminals. Pharmacologically, N-type 
Ca2+ channels are typically inhibited by the selective 
peptidergic blocker ω-conotoxin GIVA.5 
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Figure 1: Schematic representation to explain the molecular mechanisms of actions of calcium channel blockers 
(CCBs).6 
 
AZELNIDIPINE AS CALCIUM CHANNEL BLOCKER: 
IUPAC name of the Azelnidipine is (±)-(3)-(1-   diphenyl 
methyl azetidin- 3-yl)-5-isopropyl-2-amino-1, 4-dihydro-6-
methyl-4-(3- nitrophenyl)-3, 5-pyridine dicarboxylate, is a 
new dihydropyridine derivative with calcium antagonistic 
activity. Although all the existing dihydropyridine calcium 
blockers have two methyl groups located at the 2- and 6-
positions of the dihydropyridine ring, one methyl group at 
the 2-position is substituted by an amino group in the 
azelnidipine molecule. Consequently a conduct of a series of 
preclinical and clinical studies, this drug was launched into 
the market as CALBLOCK® in Japan in 2003. Azelnidipine 
occurs as two enantiomers due to an asymmetric carbon at 
the 4-position of the 1,4 dihydropyridine ring.7  
 
 
 
Figure 2: Structure of azelnidipine 
 
Azelnidipine was synthesized by Ube Industries, Ltd. and 
developed by Sankyo Co., Ltd. (currently known as Daiichi 
Sankyo Co., Ltd., Tokyo, Japan). Azelnidipine has a potent and 
sustained Blood pressure -lowering effect in various animal 
models of hypertension . It was confirmed that azelnidipine 
has renoprotective effects (such as reducing proteinuria by 
dilating efferent arterioles), as well as cardioprotective, 
insulin resistance-improving, cerebroprotective, and anti-
atherosclerotic effects.8  
The antihypertensive effect of azelnidipine is primarily based 
on the inhibition of trans-membrane Ca2+ influx through the 
voltage-dependent channels of vascular smooth muscles. 
Ca2+ channels are categorized into several subtypes, 
including L-type, T-type, N-type, P/Q-type, and R-type Ca2+ 
channels depend on their electrophysiological properties.  
Azelnidipine is selective for L-type Ca2+ channels. It has 
strong lipophilicity and affinity to membranes of vascular 
smooth muscle cells. A preclinical study showed that 
azelnidipine could not be removed from the blood vessels, 
even by washing. It is retained in the vascular wall after 
clearance from the blood and continues to stimulate a 
hypotensive effect. Unlike other dihydropyridine Calciun 
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Channel Blockers, azelnidipine does not induce reflex 
tachycardia, probably since it elicits a gradual fall in BP. In 
addition, clinical studies have demonstrated that 
azelnidipine considerably reduced heart rate and proteinuria 
in hypertensive patients by suppressing sympathetic nerve 
activity. Azelnidipine has also been confirmed to have cardio-
protective, cerebro-protective, and anti-atherosclerotic 
effects, and improves insulin resistance. Azelnidipine is used 
in the treatment of patients with hypertension, and the 
recommended dosage is 8–16 mg orally once daily. Oral 
administration of azelnidipine shows rapid, dose-dependent 
absorption.9  
Calcium channel blockers (CCBs) are not recommended for 
routine treatment in patients with heart failure with reduced 
ejection fraction, because they might reduce the myocardial 
contractility. Conversely, their effects on LV diastolic 
function are still not fully elucidated. A combination of CCB 
and an angiotensin receptor blocker could improve LV 
relaxation effectively in hypertensive patients. On the other 
hand, dihydropyridine CCBs might have unfavourable effects 
on diastolic function due to reflex tachycardia. Azelnidipine 
is a unique dihydropyridine CCB that lowers BP without 
increasing heart rate, and even slightly decreasing it. We 
previously demonstrated that azelnidipine improved LV 
relaxation in hypertensive patients with LV diastolic 
dysfunction in the prospective multicentre, Clinical impact of 
Azelnidipine on Left VentricuLar diastolic function and 
Outcomes in patients with hypertension (CALVLOC) trial.10 
Two or more antihypertensive agents to reach their target 
blood pressure (BP) are require to most of hypertensive 
patients. Currently the best therapy for preventing 
cardiovascular disease is a combination of angiotensin II 
type 1 receptor blockers (ARB)/CCB. Such combinations 
include many kinds of ARB and CCBs. Thus, differences in 
safety and efficacy among ARB/CCBs depend on the kind of 
ARB or CCB. Recent studies have shown that not all ARBs 
have the same effects, and some benefits conferred by ARBs 
may not be class (or common) effects, but rather molecular 
(or differential) effects. Furthermore, CCBs also have 
molecular effects independent of BP-lowering.11 
PHARMACODYNAMIC: 
Azelnidipine is a vasodilator that induces a gradual decrease 
in blood pressure in hypertensive patients. Different other 
member of its drug class, azelnidipine does not induce reflex 
tachycardia due to vasodilation. This is probable due to the 
fact that it elicits a gradual fall in blood pressure.It also 
exhibits a prolonged hypotensive effect and has been shown 
to have a strong anti-arteriosclerotic action in vessels due to 
its high affinity for vascular tissue and antioxidative activity. 
Clinical studies have demonstrated that azelnidipine 
markedly reduced heart rate and proteinuria in hypertensive 
patients by inhibiting sympathetic nerve activity. 
Azelnidipine has also been confirmed to have cardio-
protective, neuroprotective, and anti-atherosclerotic 
properties, and has also been found to prevent insulin 
resistance. 
MECHANISM OF ACTION: 
Azelnidipine inhibits trans-membrane Ca2+ influx through 
the voltage-dependent channels of smooth muscles in 
vascular walls. Ca2+ channels are classified into various 
categories, including L-type, T-type, N-type, P/Q-type, and R-
type Ca2+ channels. The L-type Ca2+ channels. Normally, 
calcium induces smooth muscle contraction, contributing to 
hypertension. When calcium channels are blocked, the 
vascular smooth muscle does not contract, resulting in 
relaxation of vascular smooth muscle walls and decreased 
bood pressure 
METABOLISM 
Like most members of its class, azelnidipine primarily 
undergoes first-pass hepatic metabolism. Azelnidipine is 
metabolized by hepatic cytochrome P450 (CYP) 3A4 and has 
no active metabolite product. It may interact with other 
drugs or compounds that are substrates for this enzyme. 
Azelnidipine is lipophilic and has a potent affinity for 
membranes of vascular smooth muscle cells.9, 12, 13 
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